References
1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705–714.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41–52.
3. Sherman KE, Roustrer S, Chung R, et al. Hepatitis C: prevalence in HIV-infected patients across sectional analysis of the US ACTG. Antivir Ther 2000;5(suppl 1):64–65.
4. Verucchi G, Calza L, Manfredi R, et al. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004;32:33–46.
5. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492–497.
6. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632–1641.
7. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995;9:1131–1136.
8. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002;16:813–828.
9. Sánchez-Quijano A, Andreu J, Gavilán F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995;14:949–953.
10. Soto B, Sánchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1–5.
11. García-Samaniego J, Rodríguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001;96:179–183.
12. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192:992–1002.
13. Ostapowicz G, Watson KJ, Locarnini SA, et al. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998;27:1730–1735.
14. Pessione F, Ramond MJ, Peters L, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003;23:45–53.
15. Gitto S, Micco L, Conti F, et al. Alcohol and viral hepatitis: a mini-review. Dig Liver Dis 2009;41:67–70.
16. Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206–1213.
17. Hézode C, Lonjon I, Roudot-Thoraval F, et al. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 2003;17:1031–1037.
18. Fernández-Rodriguez CM, Gutiérrez ML, Serrano PL, et al. Factors influencing the rate of fibrosis progression in chronic hepatitis C. Dig Dis Sci 2004;49:1971–1976.
19. Westin J, Lagging LM, Spak F, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat 2002;9:235–241.
20. Weaver MF, Cropsey KL, Fox SA. HCV prevalence in methadone maintenance: self-report versus serum test. Am J Health Behav 2005;29:387–394.
21. Walley AY, White MC, Kushel MB, et al. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat 2005;28:181–187.
22. Carey J, Perlman DC, Friedmann P, et al. Knowledge of hepatitis among active drug injectors at a syringe exchange program. J Subst Abuse Treat 2005;29:47–53.
23. Heimer R, Clair S, Grau LE, et al. Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction 2002;97:1277–1287.
24. Sachithanandan S, Kay E, Leader M, et al. The effect of light drinking on HCV liver disease: the jury is still out. Biomed Pharmacother 1997;51:295–297.
25. Grebely J, Genoway KA, Raffa JD, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008;93:141–147.
26. Campbell JV, Hagan H, Latka MH, et al. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend 2006;81:259–265.
27. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47:1–39.
28. Silk KJ, Horodynski MA, Rienzo M, et al. Strategies to increase health literacy in The Infant Feeding Series (TIFS): a six-lesson curriculum for low-income mothers. Health Promot Pract 2010;11:226–234.
29. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2004;39:609–629.